The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Cardiology of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China.
Food Funct. 2021 Jan 7;12(1):41-56. doi: 10.1039/d0fo02122a. Epub 2020 Nov 25.
The main goal of this work was to clarify the effects of black tea supplementation on blood pressure (BP) by performing a systematic review according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines, followed by a dose-response meta-analysis of randomized controlled trials (RCTs). Electronic search was carried out in PubMed, Embase and the Cochrane Library databases published up to March 2020. To be included, RCTs had to report the effect of black tea supplementation on systolic blood pressure (SBP) or diastolic blood pressure (DBP) in adults. A total of 13 trials, including 22 study arms were eligible for inclusion in the final quantitative analysis. It was observed that black tea supplementation significantly reduced SBP (WMD - 1.04 mmHg; 95% CI - 2.05 to -0.03; and P = 0.04) and DBP (WMD - 0.59 mmHg; 95% CI - 1.05 to -0.13; and P = 0.01) compared to the control. However, nonlinear analysis failed to indicate a significant influence of black tea flavonoid supplementation dose or duration on both SBP and DBP. Sensitivity analysis showed that no individual study had a significant impact on our results. In addition, we found no evidence for the presence of small-study effects among studies for both SBP and DBP. Thus, the favorable effect of black tea supplementation emerging from the current meta-analysis suggests the possible use of this tea as an active compound in order to promote cardiovascular health, mostly when used for longer duration (>7 days) and in men. Furthermore RCTs using different doses of black tea and various durations may contribute to confirming our conclusion.
本研究的主要目的是通过系统综述(根据 PRISMA 指南进行)澄清红茶补充剂对血压(BP)的影响,然后对随机对照试验(RCT)进行剂量反应荟萃分析。电子检索在 PubMed、Embase 和 Cochrane Library 数据库中进行,截至 2020 年 3 月发布。纳入的 RCT 必须报告红茶补充剂对成年人收缩压(SBP)或舒张压(DBP)的影响。共有 13 项试验,包括 22 个研究臂,符合最终定量分析的纳入标准。结果观察到,与对照组相比,红茶补充剂可显著降低 SBP(WMD - 1.04 mmHg;95%CI - 2.05 至 -0.03;P = 0.04)和 DBP(WMD - 0.59 mmHg;95%CI - 1.05 至 -0.13;P = 0.01)。然而,非线性分析未能表明红茶类黄酮补充剂量或持续时间对 SBP 和 DBP 有显著影响。敏感性分析表明,没有个别研究对我们的结果有显著影响。此外,我们没有发现 SBP 和 DBP 研究中存在小样本研究效应的证据。因此,当前荟萃分析中红茶补充的有利影响表明,这种茶可能作为一种活性化合物用于促进心血管健康,尤其是在使用更长时间(>7 天)和男性时。此外,使用不同剂量红茶和不同持续时间的 RCT 可能有助于证实我们的结论。